Your essential biotech, medtech, and pharma recap — no noise, just what matters.

Tuesday, September 29, 2026

⚡ Executive Takeaway

We set the delivery layer as this week's through line on Sunday and expected EASD to test it. Instead the test came a day early, from two companies that were not on the congress program, and the results split in the most instructive way possible. Kodiak's entire 178% repricing is a payment for a schedule: Zenkuda's efficacy is non inferior to aflibercept, nothing more, and the market added roughly a billion and a half dollars of value for the difference between eight injections a year and two. Mirum ran the same experiment in reverse. Its monthly arm cleared the bar, but the weekly arm beat it by eleven percentage points, and Mirum will now walk into payer negotiations arguing for the shorter interval. Delivery is the industry's battleground, exactly as framed, but the interval is not free; it is purchased with molecules that can afford it. Kodiak's could. Mirum's buyers will pay for the week. Milan spends the next three days pricing which incretins can afford theirs.

The full data tables, the deal terms, and the tariff tiers, all below. 👉 Read Full Analysis

👁 Retina

The market paid 178% for a dosing schedule, not a molecule. KOD

Kodiak Sciences reported that both Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) met their DAYBREAK Phase 3 primary endpoints, delivering vision gains non inferior to aflibercept at one year in treatment naive wet AMD (p=0.0007 and p=0.0036), per the company's release. The number that moved the stock: 54% of Zenkuda patients reached a six month dosing interval at year one under strict fluid based retreatment criteria, with 0% intraocular inflammation. Kodiak plans a Q4 2026 BLA spanning wet AMD, diabetic retinopathy, and retinal vein occlusion on five positive Phase 3 studies. Four years and seven months after tarcocimab's first failed readout, KOD closed at 89.92, up 178.0% in the first reaction session, our arithmetic from exchange settled closes.

🧬 Hepatitis Delta

Mirum's single agent cleared the bar at both doses, and the weekly arm won the argument. MIRM

Brelovitug met the Phase 3 AZURE-1 primary endpoint in chronic hepatitis delta, per Mirum's release: at Week 24, 56% of patients on 300 mg weekly and 45% on 900 mg every four weeks achieved combined virologic response and ALT normalization, versus 0% of delayed treatment controls (p<0.0001 for both). Safety was clean, with zero serious or Grade 3 or higher events in either treated arm. Mirum plans a BLA in H1 2027 and a potential US launch in Q4 2027, positioning the subcutaneous single agent against Gilead's Europe approved bulevirtide and Vir's combinations, per Fierce Biotech. MIRM closed down 1.9% at 87.96 in a double catalyst first reaction session, its first trade since Friday's post close Atebrioz approval; we assign no cause to the fade.

💰 Deals and Capital

AstraZeneca bought a seat on ivonescimab's cap table instead of writing a license. SMMT | AZN | MRK

After Monday's close, AstraZeneca announced a $2.0 billion investment in newly issued Summit Therapeutics preferred stock, convertible into roughly 12.0% of the company, alongside a clinical collaboration pairing its Claudin-18.2 ADC sonesitatug vedotin with ivonescimab in gastrointestinal cancers and a memorandum of understanding covering further ADC combinations, per AstraZeneca's release. No license, no milestones, no royalty; each company keeps its own drug and they split trial costs. Closing is anticipated within a week, and ivonescimab's FDA decision is due November 14. SMMT closed at 15.48 before the news, so Tuesday is the first reaction session. Separately, Merck licensed SPR2015, a preclinical oral KRAS G12D inhibitor, from Shanghai based SciBrunch for $400 million upfront and up to $2.13 billion total, per Fierce Biotech, another nine figure upfront for a Chinese asset that has never dosed a patient.

🧠 Regulatory

The FDA approved a new Parkinson's mechanism and turned away a lung cancer ADC on the same day. ABBV | MRK

AbbVie won approval for Juvmo (tavapadon), a once daily selective D1/D5 dopamine receptor agonist, for Parkinson's disease in adults, both as monotherapy in early disease and as adjunct to levodopa in patients with motor fluctuations, per AbbVie's release; in TEMPO-3, it added 1.7 hours of on time without troublesome dyskinesia versus 0.6 for placebo, and US availability is expected in October. ABBV closed up 0.7%. The same day, Merck and Daiichi Sankyo voluntarily withdrew the ifinatamab deruxtecan accelerated approval filing in previously treated extensive stage small cell lung cancer after the FDA said the Phase 2 dataset fell short of accelerated approval requirements, per Fierce Biotech, the second regulatory blow to their $4 billion upfront ADC alliance. Phase 3 IDeate-Lung02 is nearly enrolled; the bar for single arm oncology approvals keeps rising.

💉 Obesity and EASD

Roche's muscle preservation bet died a week before the field's biggest stage. RHHBY | NVO | VKTX

Genentech discontinued emugrobart, its anti myostatin antibody meant to preserve muscle during GLP-1 weight loss, after a Phase 2 Gyminda interim analysis found success unlikely, per Fierce Biotech; the antibody had already missed in SMA and FSHD this year, and Chugai regains the program. The muscle preservation category just lost its most advanced large pharma sponsor. In Milan, EASD's opening day carried no major readouts; the week's data starts this morning with the CagriSema REIMAGINE 1 body composition analysis, followed Wednesday by retatrutide's TRIUMPH-2 diabetes results, Mounjaro's SURPASS-CVOT outcomes data, and the OCTANE Wegovy pill switching study. Viking closed at 33.03, down 7.1% and now 5.6% below its $35.00 offer price from last week's raise, a repricing into the readouts; we assign no cause.

🩺 Medtech and Policy

The CGM industry mapped its own awareness gap as tariffs reach day zero. DXCM

Dexcom used EASD's opening day to publish its State of Type 2 report, surveying over 800 clinicians and 2,500 people with type 2 diabetes across eight countries: 89% of clinicians say CGM helps them assess adherence between visits, yet 55% of patients report limited knowledge of the technology, and 58% of GLP-1 users pair CGM with their medication versus 27% of non insulin users, per the report. The gap between clinician conviction and patient awareness is the category's growth map. And today, Section 232 tariffs on patented pharmaceutical imports reach their general effective date: 100% by default, 20% with an approved onshoring plan, 15% for the EU, Japan, South Korea, Switzerland, and Liechtenstein, and 10% for the UK, with generics excluded, per trade counsel summaries of the proclamation. Seventeen large companies have been paying since July 31. We will report observed effects, not predictions.

📋 Quick Hits

📖 In Today's Full Analysis

Be sure to read the full article for all the details, including:

👉 Read the full breakdown →

The delivery layer got its first two graded tests a day early and split them, which is more useful than sweeping them. Milan takes over from here: CagriSema this morning, the retatrutide and OCTANE double Wednesday. What are you watching? Reply to this email.

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →